ALLK AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
ALLK Current Performance
5.79%
Allakos inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to ALLK
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
GUTS | Fractyl health inc | - | 2 | 2 | 2 | 1 | |
AVBP | Arrivent biopharma inc | - | 4 | 3 | 3 | 1 | |
INTS | Intensity therapeutics inc | - | 5 | 3 | 1 | 1 | |
ALDX | Aldeyra therapeutics inc | 2 | 3 | 2 | 3 | 1 | |
PRME | Prime medicine inc | - | 2 | 4 | 2 | 1 |
- GUTS Fractyl health incValue -Trend 2Swing Trading 2Whale Interest 2Dividend 1See more
ALLK Profile
Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Company's most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. In addition to mast cell inhibition, AK006 reduced human tissue mast cells via ADCP in the presence of activated macrophages. The Company is also developing lirentelimab (AK002) and, in conjunction with the Phase II, lirentelimab results in atopic dermatitis and chronic spontaneous urticaria.